Novel Targeted Therapy for AML
AML 的新型靶向治疗
基本信息
- 批准号:9247879
- 负责人:
- 金额:$ 33.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-15 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaApoptosisAttenuatedBiogenesisCell ProliferationCellsCentrosomeClinical DataCombined Modality TherapyDNA RepairDevelopmentDiagnosisDisease remissionDislocationsFLT3 geneGenesGrowthHDAC4 geneHistone Deacetylase InhibitorHistonesHumanIn VitroKnowledgeMolecular ChaperonesMutationMyeloproliferative diseaseN-terminalNPM1 geneNucleic AcidsPathogenicityPatientsPhenotypePhosphoproteinsProtein Tyrosine KinaseProteinsRefractoryRelapseReportingRibosomesRoleTestingTranscriptional RegulationTreatment-related toxicityTretinoinTumor Suppressor ProteinsTyrosine Kinase Inhibitorbasecell growthchemotherapyclinical developmentfounder mutationgain of functionhigh throughput screeningin vivoknock-downmouse modelmutantnew therapeutic targetnovelnucleophosminoutcome forecastpre-clinicalpublic health relevancetargeted treatment
项目摘要
DESCRIPTION (provided by applicant): There is a clear unmet need to develop novel, targeted and safer therapies for acute myeloid leukemia (AML). Approximately 30% of AML carry a heterozygous mutation in the nucleophosmin 1 (NPM1), which results in the cytoplasmic dislocation of the mutant NPM1 (mtNPM1). Wild-type NPM1 (wtNPM1) is a nucleolar phosphoprotein, which functions as a molecular chaperone for proteins and nucleic acids (4). The N-terminal conserved oligomerization domain of NPM1 is critical for its multiple functions. In AML, presence of the cytoplasmic, dislocated mtNPM1 attenuates the levels of the nucleolar wtNPM1. As a founder mutation in AML, mtNPM1 is a haploinsufficient tumor suppressor of myeloid malignancies and appears to also confer a gain of function for the AML phenotype. Although its presence is associated with a relatively better prognosis in AML, mtNPM1 is often co-expressed with mutant FLT-3-ITD (internal tandem duplication), which represents an aggressive and relatively treatment-refractory sub-type of AML. Recently, we reported that knockdown of the levels and/or function of NPM1 induces growth arrest, differentiation and apoptosis of AML cells with mtNPM1, as well as sensitizes the AML cells to differentiation induced by all-trans retinoic acid (ATRA). Therefore, there is a strong rationale and need for fully evaluating the anti-AML efficacy and its mechanism following the targeted knockdown of the level and/or function of NPM1 along with a differentiation inducing agent or a FLT3-TKI. Based on this, the objectives of this proposal are to fill the gap in our knowledge about the mechanism by which knockdown of NPM1 induces differentiation and apoptosis and increases sensitivity of AML cells with mtNPM1 to differentiation-inducing therapy and FLT3-TKI. Proposed in vitro and in vivo studies in mouse models will create the supportive pre-clinical data for further clinical development of the novel combinations of NPM1 antagonist-based therapy of AML. These studies will test the unifying hypothesis that knockdown of NPM1 levels/function overcomes differentiation arrest and sensitizes AML cells that express mtNPM1 to differentiation-inducing agents, as well as sensitizes AML cells that co-express FLT3-ITD and mtNPM1 to FLT3-TKI. The specific aims of the proposal are: AIM 1: To determine the in vitro and in vivo effects of the knockdown of NPM1 (mtNPM1 versus wtNPM1 plus mtNPM1) levels or function on cell growth, differentiation and survival of cultured and patient-derived primary AML cells expressing mtNPM1. AIM 2: To determine the sensitizing effect of knockdown of NPM1 levels or function on the in vitro and in vivo activity of differentiation- inducing agents, e.g., all-trans retinoic acid (ATRA) or a histone deacetylase (HDAC) inhibitor, against cultured and primary AML cells. AIM 3: To determine the in vitro and in vivo anti-AML activity of combined targeting of NPM1 and FLT3-ITD in cultured and primary AML cells that co-express mtNPM1 and FLT3-ITD. Overall, these aims will establish NPM1 as a 'druggable' target and pave the way for performing high throughput screening and development of novel compounds that target NPM1 for the therapy of AML expressing mtNPM1.
描述(申请人提供):开发治疗急性髓系白血病(AML)的新的、有针对性的和更安全的疗法显然是一个尚未得到满足的需求。约30%的AML携带核磷蛋白1(NPM1)杂合性突变,导致突变型NPM1(MtNPM1)胞质错位。野生型NPM1(WtNPM1)是一种核仁磷酸蛋白,其功能是蛋白质和核酸的分子伴侣(4)。NPM1的N端保守的寡聚区是其多功能的关键。在AML中,细胞质错位的mtNPM1的存在会减弱核仁wtNPM1的水平。作为AML的创建者突变,mtNPM1是髓系恶性肿瘤的单倍体缺陷肿瘤抑制基因,似乎也赋予了AML表型功能的获得。尽管mtNPM1的存在与AML相对较好的预后有关,但mtNPM1经常与突变的Flt-3-ITD(内部串联复制)共表达,突变的Flt-3-ITD代表了一种侵袭性和相对治疗难治的AML亚型。最近,我们报道了下调NPM1的水平和/或功能可以通过mtNPM1诱导AML细胞的生长停滞、分化和凋亡,并使AML细胞对全反式维甲酸(ATRA)诱导的分化敏感。因此,有必要在靶向下调NPM1的水平和/或功能的同时,结合分化诱导剂或Flt3-TKI,全面评估抗AML的疗效及其机制。基于此,本研究的目的是填补我们对NPM1基因敲除诱导分化和凋亡机制的认识的空白,并增加携带mtNPM1的AML细胞对分化诱导治疗和Flt3-TKI的敏感性。提出的在小鼠模型上的体外和体内研究将为进一步开发以NPM1拮抗剂为基础的AML治疗的新组合的临床前支持数据。这些研究将检验一个统一的假设,即下调NPM1水平/功能可以克服分化停滞,并使表达mtNPM1的AML细胞对分化诱导剂敏感,以及使共同表达Flt3-ITD和mtNPM1的AML细胞对Flt3-TKI敏感。该提案的具体目的是:目的1:确定下调NPM1(mtNPM1与wtNPM1+mtNPM1)水平或功能对培养的和患者来源的原代表达mtNPM1的AML细胞的生长、分化和存活的影响。目的:研究下调NPM1水平或功能对全反式维甲酸(ATRA)或组蛋白脱乙酰酶(HDAC)抑制剂等分化诱导剂对培养和原代AML细胞体外和体内活性的增敏作用。目的:检测NPM1和Flt3-ITD联合靶向在体外和原代共表达mtNPM1和Flt3-ITD的AML细胞中的抗AML活性。总体而言,这些目标将使NPM1成为“可用药”的靶标,并为进行高通量筛选和开发针对NPM1的新化合物以治疗表达mtNPM1的急性髓系白血病铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAPIL BHALLA其他文献
KAPIL BHALLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAPIL BHALLA', 18)}}的其他基金
Novel combination therapy for AML expressing mutant RUNX1
表达突变体 RUNX1 的 AML 的新型联合疗法
- 批准号:
10698087 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Novel combination therapy for AML expressing mutant RUNX1
表达突变体 RUNX1 的 AML 的新型联合疗法
- 批准号:
10276033 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Novel combination therapy for AML expressing mutant RUNX1
表达突变体 RUNX1 的 AML 的新型联合疗法
- 批准号:
10473712 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
靶向转录组失调作为骨髓增殖后肿瘤 (MPN) sAML 的治疗方法
- 批准号:
10595080 - 财政年份:2020
- 资助金额:
$ 33.2万 - 项目类别:
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1
表达体细胞或种系突变体 RUNX1 的 AML 的生物学和新疗法
- 批准号:
10531564 - 财政年份:2020
- 资助金额:
$ 33.2万 - 项目类别:
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
靶向转录组失调作为骨髓增殖后肿瘤 (MPN) sAML 的治疗方法
- 批准号:
10364667 - 财政年份:2020
- 资助金额:
$ 33.2万 - 项目类别:
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1
表达体细胞或种系突变体 RUNX1 的 AML 的生物学和新疗法
- 批准号:
10308449 - 财政年份:2020
- 资助金额:
$ 33.2万 - 项目类别:
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
基于BET蛋白拮抗剂的套细胞淋巴瘤靶向治疗
- 批准号:
9888204 - 财政年份:2017
- 资助金额:
$ 33.2万 - 项目类别:
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
基于BET蛋白拮抗剂的套细胞淋巴瘤靶向治疗
- 批准号:
10132260 - 财政年份:2017
- 资助金额:
$ 33.2万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 33.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 33.2万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 33.2万 - 项目类别:
Discovery Grants Program - Individual